ABSTRACT
Prostate cancer is the most common non-skin cancer and the second leading cause of cancer mortality in US men.
Screening involves digital rectal examination (DRE) and serum prostate- specific antigen (PSA) testing.
Diagnosis of prostate cancer is made from transrectal ultrasound-guided prostate needle biopsy.
Staging (TNM) and grading (Gleason score) information is directly associated with prognosis.
Treatment for clinically localized prostate cancer should be individualized, based on the aggressiveness of the tumor, patient life expectancy, and patient preference.
Definitive, curative therapy should be considered in men with localized prostate cancer and greater than 10 years of life expectancy.
Treatments for localized prostate cancer include expectant management, radical prostatectomy, radiation, and cryosurgery.
